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Background: The aging process leads to a potential decline in immune function and 
adversely affects the gut microbiota. To date, many in vitro and in vivo studies focused 
on the application of synbiotics (prebiotics combined with probiotics) as a promising 
dietary approach to affect gut microbiota composition and improved functioning of the 
immune system. However, studies using synbiotic preparations often have the limitation 
that it remains unclear whether any effect observed is a result of the prebiotic or probiotic 
or a synergistic effect of the combined supplement.
Objectives: We investigated the effects of a probiotic Lactobacillus rhamnosus GG and 
pilus-deficient L. rhamnosus GG-PB12 combined with Promitor™ Soluble Corn Fiber 
(SCF, a candidate prebiotic) on fecal microbiota, metabolism, immunity, and blood lipids 
in healthy elderly persons. A prospective, double-blind, placebo controlled, randomized, 
single-centered, crossover study in 40 healthy elderly subjects (aged 60–80 years) was 
carried out. Volunteers were randomized to consume either probiotic and prebiotic as 
synbiotic, prebiotic or placebo (maltodextrin) during 3  weeks. Three-week washout 
periods separated all the treatments. We assessed effects upon blood lipids, glucose, 
cytokines, natural killer (NK) cell activity, phenotype, and intestinal microbiota composi-
tion. SCF decreased IL-6, which was not observed with the synbiotics.
results: Consumption of L. rhamnosus GG combined with SCF increased NK  cell 
activity compared to baseline in females and the older group. In the fecal microbiota 
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analyses, the strongest community shifts were due to L. rhamnosus GG combined with 
SCF and SCF treatments. L. rhamnosus GG combined with SCF and L. rhamnosus 
GG-PB12 combined with SCF significantly increased the genus Parabacteroides. 
L. rhamnosus GG combined with SCF and SCF increased concentrations of 
Ruminococcaceae Incertae Sedis. Oscillospira and Desulfovibrio slightly decreased in 
the L. rhamnosus GG combined with SCF group, whereas Desulfovibrio decreased also 
in the L. rhamnosus GG-PB12 combined with SCF group. L. rhamnosus GG combined 
with SCF reduced total cholesterol and LDL-cholesterol in volunteers with initially ele-
vated concentrations. C-reactive protein significantly decreased during L. rhamnosus 
GG-PB12 combined with SCF intervention compared to baseline.
Conclusion: In conclusion, the synbiotic combination of L. rhamnosus GG with SCF 
showed a tendency to promote innate immunity by increasing NK cell activity in elderly 
women and in 70 to 80-year-old volunteers and decreased TC and LDL-c in hyper-
cholesterolemic patients. In addition, L. rhamnosus GG-PB12 combined with SCF 
demonstrated an increase in NK cell activity compared to SCF alone in older volunteers. 
We also found significant positive effects on the immune response, evidenced by a 
decrease of the pro-inflammatory cytokine IL-6. Therefore, dietary intervention with 
L. rhamnosus GG combined with SCF could be of importance in elderly as an attractive 
option for enhancement of both the microbial and immune systems.
Keywords: Lactobacillus rhamnosus GG, Lactobacillus rhamnosus GG-PB12, pilus-deficient, Soluble Corn Fiber, 
fecal microbiota, metabolism, immunity
inTrODUCTiOn
The human gastrointestinal (GI) tract supports a rich and com-
plex microbiota, whose composition and activities play important 
roles in nutrition, immunology, and certain disease processes. 
The composition of this microbial community is host specific, 
evolving throughout an individual’s lifetime and is susceptible to 
both exogenous and endogenous modifications. Recent interest 
in the function of this “organ” has illuminated a central position 
in health and disease. However, mechanisms by which the micro-
biota exerts its beneficial or detrimental influences remain largely 
undefined; thus, research in this area is key to future recommenda-
tions. A progressive increase in the proportion of elderly persons 
has led to heightened attention to their physiological needs. It is 
well known that immune function becomes compromised with 
age, an effect known as immune-senescence (1), which compro-
mises the ability to respond to infections and develop increased 
protection after vaccination (2, 3). It may therefore contribute 
toward a higher mortality rate in older people and it has also been 
reported that in older people, the numbers and species diversity 
of putatively beneficial gut microbial groups, such as lactobacilli 
and bifidobacteria, as well as butyrate producers are reduced 
(4, 5). Appropriate dietary intervention is an attractive, safe, 
and non-invasive way to impact on gut bacteria and subsequent 
functioning of the immune system and has been proposed as an 
avenue to maintain microbiome homeostasis during aging (6). 
The use of probiotics, as live microbial food additions, is one such 
route (7). Experimental and clinical studies have suggested that 
probiotic supplementation may have beneficial effects on serum 
lipid profiles. Human studies have reported that certain probiotic 
strains boost natural killer (NK) cell (8) and phagocytic activities 
(8, 9) in healthy volunteers and may exert beneficial effects in 
inflammatory and atopic diseases, possibly by modulating pro- 
and anti-inflammatory cytokines (10). However, there are few 
studies examining the effect of probiotics on the immune function 
of elderly persons. Evidence exists on immune-stimulating effects 
of certain probiotics and the potential to use prebiotics to increase 
the levels of such bacteria, the latter being a selectively metabo-
lized microbial substrate. Furthermore, by providing a probiotic 
at the same time as a prebiotic, conditions for survival of the live 
addition should be enhanced. Promitor™ Soluble Corn Fiber 
(SCF) is a well-known maize-derived source of dietary fiber with 
potential selective fermentation properties (11–14). Previous 
in  vivo study has demonstrated the optimum prebiotic dose 
response of SCF (15). Previous in vitro work led to the selection of 
a probiotic bacterium, Lactobacillus rhamnosus GG, which com-
bined with SCF, showed anti-pathogenic effects against E. coli and 
Campylobacter spp. (Costabile et al., unpublished data). Because 
of their strong mucus-binding properties, pili are thought to be 
major factors for binding and persistence of L. rhamnosus GG in 
the GI tract. Our purpose was to investigate the effects of L. rham­
nosus GG combined with SCF (i.e., synbiotics) and SCF alone, 
on the fecal microbiota, metabolism, immunity, and blood lipids 
in healthy elderly subjects. Moreover, to address the essential 
role of the pili of L. rhamnosus GG, the pilus-less L. rhamnosus 
GG derivative LGG-PB12 was included into the study.
FiGUrE 1 | Flow of the study participants through the intervention.
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MaTErialS anD METHODS
intervention Study and Subjects
A total of 80 potential healthy volunteers (aged 60–80 years) were 
contacted from the University of Reading and surrounding area 
through the Hugh Sinclair Unit of Human Nutrition volunteer 
database, and through advertisements within the local commu-
nity between September 2014 and January 2015. Of the first 75 
responded, 60 were screened and we were recruited 40 volun-
teers; 37 participants completed the study with 3 drop-out due to 
personal circumstances (Figure 1). The study was powered to get 
80% statistical power (Hedwig Harvard Software) on the basis of 
the data from previous intervention studies in human volunteers 
conducted on bacteriology. We obtained written consent from 
each person and selection took place following determinations 
of health status through a medical interview and adherence to 
the inclusion/exclusion criteria. Inclusion criteria were as follows: 
aged 60–80 years, good general health, and willing to participate 
in the entire study. We excluded volunteers with evidence of 
physical or mental disease, history of drug abuse, severe allergy, 
or a history of severe abnormal drug reaction and smokers. Intake 
of an experimental drug within 4  weeks before study, former 
participation in a prebiotic, probiotic, or laxative trial within 
2 weeks, or use of antibiotics within 6 months before the study, 
chronic constipation, diarrhea or other chronic GI complaint 
(for example, irritable bowel syndrome), lactose intolerance, 
and gluten allergy were all exclusion criteria. Individuals with a 
clinically important renal, hepatic, endocrine (including diabetes 
mellitus), pulmonary, pancreatic, neurologic, dermatological, 
urogenital/rectal, dermatological, or lymphatic disorder and 
any major cardiovascular condition were also excluded, as were 
those with a recent history, or the presence, of cancer. Any intake 
of drugs active on GI motility, antibiotic treatment, or any class 
of laxative was not permitted. Volunteers recorded any medica-
tion taken throughout the duration of the study in diaries. We 
instructed volunteers not to alter their usual diet or fluid intake 
during the trial periods; however, they were asked to refrain from 
consuming prebiotics and probiotics, including daily fiber intake, 
live yogurts, and fermented milk drinks. All volunteers signed 
an informed consent form, and agreed to conform to the trial 
guidelines and provide notification of any non-compliance.
Study Design and Treatments
The study was registered as a clinical trial (http://clinicaltrials.
gov ID: NCT03168503) and was conducted according to the 
Declaration of Helsinki following Good Clinical Practice (GCP). 
The study was approved by the University of Reading Research 
Ethics Committee (Ethics reference number UREC14/06). The 
study was designed as a prospective, double-blind, randomized, 
placebo-controlled, single-centered crossover study with a 
FiGUrE 2 | Saimes study design. The study was designed as a prospective, double-blind, randomized, placebo-controlled, single-centered crossover study with  
a 14 days run-in period prior to the beginning of the study, when volunteers were required to refrain from any probiotic or prebiotic containing food or drinks and 
control the fiber levels. The microbiota was analyzed from fecal samples taken prior to the intervention (time point 0) and at the end of the 3-week interventions  
(time points 21, 63, 105, and 147).
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2-week run-in period prior to the beginning of the study, when 
volunteers were required to refrain from any probiotic or prebi-
otic containing food or drinks and record a 4-day food diary, 
including one weekend day, to assess habitual diet (Figure  2). 
An Excel-based covariate adaptive randomization program (16) 
to enter four intervention arms randomized the volunteers: L. 
rhamnosus GG-PB12 combined with SCF, L. rhamnosus GG 
combined with SCF, SCF alone, or placebo (maltodextrin) strati-
fied by age, gender, and BMI. The SCF treatment was designed 
and confirmed by previous study to provide a total of 6 g from 
SCF (Promitor™ SCF) (equivalent to 8  g/fiber delivered) (15) 
and was provided by Tate & Lyle, France, as dry powders and 
were consumed as 250 mL beverages once daily. The probiotics 
strains were obtained from Valio Ltd and at the dose of 1 × 1010 
CF g. The subjects consumed one sachet (12 g) every day dur-
ing 3  weeks for each treatment, with 3-week washout periods 
between treatments. We collected overnight 10 h-fasting venous 
blood and one fecal sample in the morning at baseline and at the 
end of each intervention period for analyses. Fecal samples were 
collected weekly in fecal collection kit (FC 2040, Laboratories 
Ltd., UK) and volunteers were asked to keep them at −80°C until 
the visit day when they were transferred to the laboratory for all 
the analysis. Throughout the pre-treatment and treatment peri-
ods, volunteers recorded details of bowel habits including stool 
frequency and consistency (Bristol stool scale), stomach or intes-
tinal bloating, abdominal pain, and incidence and frequency of 
flatulence and stomach noises. They also completed four-day diet 
records in the week before baseline and each end-of-treatment 
clinic visit. These were analyzed using the Food Processor SQL 
Nutrition Analysis and Fitness 8.6.0 software (ESHA Research, 
Salem, OR, USA). They completed a GI symptom survey at 
baseline and at the end of each treatment period.
Preparation of Peripheral Blood 
Mononuclear Cells (PBMC)
Fasted blood samples (10 h-fasting) were taken from volunteers 
in sodium heparin vacutainer tubes (Greiner Bio-One Ltd., 
Gloucestershire, UK). Blood was layered over an equal volume 
of lympholyte (Cedarlane Laboratories Limited, Tyne & Wear, 
UK) and centrifuged at 930 × g for 15 min at room temperature. 
Plasma was removed into a sterile tube and stored at −80°C until 
further use. Cells were harvested from the interface, washed 
once, resuspended in RPMI 1640 medium (Autogen Bioclear, 
Wiltshire, UK) containing 0.75  mM glutamine (Autogen 
Bioclear, Wiltshire, UK), and the above steps were then repeated 
to achieve a lower degree of erythrocyte contamination. The 
pellet was finally resuspended in the same medium.
Preparation of Other Samples
Blood was collected by serum separator vacutainer tube (BD 
Biosciences, Oxford, UK) and centrifuged at 2,095 × g for 10 min. 
Aliquots of serum were stored at −20°C for later analysis of total 
cholesterol, HDL-cholesterol, triacylglycerol, non-esterified fatty 
acids (NEFA), glucose, and C-reactive protein (CRP).
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Blood lipids, Glucose, and immune/
inflammatory Markers
Concentrations of serum total cholesterol, HDL-cholesterol, tria-
cylglycerol, NEFA, glucose, and CRP were evaluated by iLab 
600 (all kits and equipment from Instrumentation Laboratory, 
Warrington, UK).
Cytokine analysis
We measured the production of IL-1β, IL-6, IL-8, IL-10, IL-12p70, 
and TNF using Cytometric Bead Array (CBA) multiplex kits 
(BD Biosciences, Oxford, UK) by flow cytometry according to 
the manufacturer’s instructions. BD™ CBA analysis software 
(BD Biosciences, Oxford, UK) was used to perform data analysis.
nK Cell activity
Freshly prepared PBMC were adjusted to a concentration of 
5 ×  106 cells/mL. Viable target cells (K562 cell line) were enu-
merated by microscopy of trypan blue-stained cell preparations, 
and 5 ×  106 cells collected and washed twice with PBS before 
incubation with carboxyfluorescein diacetate succinimidyl ester 
(CFDA-SE) (1 µg/mL) (Sigma, Dorset, UK) for 45 min at 37°C 
in an air/CO2 (19:1) atmosphere. Following incubation, target 
cells were washed twice and resuspended in 1 mL of complete 
medium composed of RPMI 1640 medium, 0.75 mM glutamine, 
and 10% (v/v) newborn calf serum (Sigma, Dorset, UK). PBMC 
were incubated with CFDA-SE-labeled target cells for 2 h at 37°C 
in an air/CO2 (19:1) atmosphere, at effector to target cell ratios of 
100:1, 50:1, 25:1, and 12.5:1. Twenty microliters of PI at 1 mg/mL 
were added to the samples prior to analysis by flow cytometry. 
Samples were acquired using a FACSCanto II flow cytometer 
(BD Biosciences, San Jose, CA, USA), and data analyzed using 
FACSDiva v6 software (BD Biosciences, San Jose, CA, USA). The 
results were expressed as percent lysis of the target cells.
lymphocyte/nK Cells Phenotype analysis
Peripheral blood mononuclear cells were stained with appropri-
ate combinations of fluorescently labeled mouse anti-human 
monoclonal antibodies for discrimination between different 
lymphocyte subsets. Monoclonal antibodies were conjugated to 
fluorescein isothiocyanate, phycoerythrin (PE), or (Cy-7 PE). 
PBMC were incubated with fluorescently labeled monoclonal 
antibodies (all from BD Biosciences, Oxford, UK) for 20 min at 
room temperature in the dark and washed by FACS Wash solution 
[1% (w/v) BSA, 0.1% (w/v) sodium azide in PBS] twice before 
fixing with FACS Fix solution [2% (w/v) paraformaldehyde, pH 
7.4]. The fixed cells were analyzed by flow cytometry within 24 h. 
At least 50,000 lymphocytes were acquired using a FACSCanto II 
flow cytometer (BD Biosciences, San Jose, CA, USA), and data 
were analyzed using FlowJo V 10.0.8 software (BD Biosciences, 
San Jose, CA, USA). Isototypic controls were used to minimize 
electronic noise. Using side scatter and forward scatter, a gate was 
drawn in lymphocyte populations. Anti-CD3 and anti-CD56 
mAb (present in all tubes) were used to define three cells popula-
tions: conventional T cells (CD3+CD56−), conventional NK cells 
(CD3−CD56+), and NKT  cells (CD3+CD56+). Anti-CD56 and 
anti-CD16 mAb (present in all tubes) were used to further divide 
NK  cells based in CD56 expression into two subsets: CD56dim 
and CD56bright. Gates strategies were designed based on Almeida-
Oliveira et  al. (17). Results of phenotypes were expressed as 
percentage of the subsets or within the cell group specified.
Dna Extraction and Quantitative PCr 
analysis
DNA extraction from feces was carried out using the RBB 
method as described by Salonen et al. (18). Following cell lysis 
and precipitation of nucleic acids, QIAamp DNA Minikit was 
used for further purification of the DNA. Afterward, compliance 
of the study subjects to the trial was verified using quantitative 
PCR assays. The assays were designed to target the position of 
one of the mutations, 443187, in srtC1 gene in L. rhamnosus 
GG-PB12 genome (19) (Figure S1 in Supplementary Material). 
Primers for both L. rhamnosus GG and GG-PB12 assays 
were the same (for 5′-AGTGCGACTATTAGCTTTA-3′ and 
Rev 5′-GGATCTTGTGACCTTAATG-3′), while the probes 
contained one nucleotide difference (L. rhamnosus GG: 5′-
(FAM) TTGTTCCACCAAACC (MGB-NFQ)-3′; L. rhamnosus 
GG-PB12: 5′-(FAM) TTGTTTCACCAAACC (MGB-NFQ)-3′, 
nucleotide difference marked in bold). Probes were non-fluo-
rescent quenched minor groove binder (NFQ-MGB) hydrolysis 
probes with 6-fluorescein amidite (6-FAM) as the fluorophore. 
Nucleotide oligo (5′-CGACTATTAGCTTTAATTTGTTC-3, Tm 
48°C) was used in the L. rhamnosus GG-PB12 assay to reduce 
potential non-specific signal from strain GG. The oligo was 
designed so that it anneals to the binding site of the L. rhamnosus 
GG-specific probe before the temperature reaches the probe anneal-
ing temperature and blocks the binding site of the probe. HOT 
FIREPol® Probe qPCR Mix Plus with ROX (Solis BioDyne Ltd.) 
was used in the qPCRs with program 15 min at 95°C, 20 s at 95°C, 
and 1  min at 60°C, for 35 cycles. 25  ng of DNA was used per 
reaction in a total volume of 20 µL. In addition, total bacteria were 
quantitated using an qPCR assay described by Nadkarni et  al. 
(20), with total DNA quantity of 0.5 ng per reaction and using 
master mix HOT FIREPol® EvaGreen® qPCR Mix Plus (Solis 
BioDyne Ltd.). Measurements were performed with Stratagene 
MX3005P real-time PCR equipment and analysis of the data was 
performed using MxPro qPCR Software version 4.1 (Stratagene).
intestinal Microbiota Profiling analyses
Comprehensive intestinal microbiota profiling and phylogenetic 
analysis was carried out with 16S rRNA amplicon sequencing by 
Illumina Miseq. In the paired-end mode, the variable region V3–
V4 was sequenced, using primers (CTACGGGNGGCWGCAG 
and GACTACHVGGGTATCTAATCC). However, we only kept 
the forward reads, truncated to 150 bases, as we have observed, 
using artificial microbial communities, that longer reads result in 
distorted microbiota compositions. Pre-processing and statistical 
analyses of the reads were done using the R package mare (Korpela 
2016 mare: Microbiota Analysis in R Easily. R package version 
1.0). To eliminate sequencing errors, we discarded all unique 
reads occurring <100 times in the total dataset. Taxonomic 
annotation of the reads was conducted using USEARCH (Edgar 
2010 Bioinformatics).
TaBlE 3 | Blood pressure in each group after the treatment (n = 37).
Systolic (mm Hg) Diastolic (mm Hg)
Female Male Female Male
Baseline 136.62 ± 18.26 135.27 ± 11.29 73.12 ± 7.98 77.82 ± 6.59
Placebo 132.46 ± 18.11 132.20 ± 12.80 71.48 ± 8.09 75.00 ± 7.90
L. rhamnosus GG + SCF 135.40 ± 20.72 139.70 ± 15.27 71.96 ± 8.74 78.70 ± 5.48
L. rhamnosus GG-PB12 + SCF 133.92 ± 19.17 132.20 ± 9.62 70.96 ± 8.18 77.00 ± 7.79
Soluble Corn Fiber 134.42 ± 22.29 131.83 ± 12.34 70.08 ± 7.91 75.50 ± 4.66
All values are means ± SD. No significant differences were shown between baseline and post-intervention (two-way analysis of variance with Bonferroni correction).
TaBlE 2 | Change in anthropometric measurements in all study participants (n = 37) between baseline and 3 weeks intervention period with placebo (maltodextrin), 
Lactobacillus rhamnosus GG + SCF, L. rhamnosus GG-PB12 + SCF, and SCF only.
Weight (kg) BMi (kg/m2) Waist (cm)
Female Male Female Male Female Male
Baseline 68.01 ± 7.42 85.18 ± 10.86 25.48 ± 3.31 27.11 ± 2.21 89.85 ± 8.65 97.78 ± 10.24
Placebo 67.71 ± 7.49 84.46 ± 11.06 25.52 ± 3.36 27.40 ± 2.41 86.40 ± 9.09 97.40 ± 12.29
L. rhamnosus GG + SCF 68.01 ± 7.48 85.18 ± 11.27 25.58 ± 3.55 27.55 ± 2.44 86.95 ± 9.00 99.05 ± 11.32
L. rhamnosus GG-PB12 + SCF 67.60 ± 6.82 83.26 ± 10.86 25.78 ± 3.31 26.97 ± 2.41 86.02 ± 9.51 97.50 ± 7.93
SCF 67.58 ± 6.70 84.98 ± 10.62 25.81 ± 3.32 27.32 ± 2.31 88.46 ± 8.25 99.40 ± 9.12
SCF, Promitor™ Soluble Corn Fiber.
Values represent means ± SD. No significant difference was shown between baseline, intervention, and post-intervention. Two-way analysis of variance with Bonferroni correction 
were used were used to assess treatment, time, and treatment by time interaction effects.
TaBlE 1 | Average, self-reported, gastrointestinal symptom scores for stool 
frequency, consistency, bloating, flatulence, and abdominal pain, over the 3-week 
intervention period for the placebo, synbiotics, and SCF for each treatment group 
(n = 37).
Placebo Lactobacillus 
rhamnosus 
GG + SCF
L. rhamnosus 
GG-PB12 + SCF
SCF
Stool 
frequencya
1.95 ± 1.30 1.95 ± 1.51 1.98 ± 1.65 1.99 ± 1.56
Stool 
consistency
3.82 ± 0.99 3.86 ± 1.06 4.15 ± 0.99 3.81 ± 1.05
Intestinal 
bloatingb
0.22 ± 0.44 0.17 ± 0.39 0.14 ± 0.26 0.15 ± 0.39
Flatulenceb 0.46 ± 0.50 0.56 ± 0.57 0.51 ± 0.62 0.53 ± 0.56
Abdominal 
painb
0.11 ± 0.19 0.09 ± 0.21 0.15 ± 0.31 0.15 ± 0.32
SCF, Promitor™ Soluble Corn Fiber.
aNumber of stools per day. Estimated using the Bristol stool chart (scale with seven 
stool types; Type 1—hard to Type 7—entirely liquid).
bOverall scale from 0 to 3 (0—no symptoms; 1—very mild symptoms to 3—very severe 
symptoms). All values are means ± SD. No significant differences were shown between 
baseline and post-intervention or between treatments and control. Two-way analysis of 
variance with Bonferroni correction were used to assess treatment, time, and treatment 
by time interaction effects.
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Statistics
Data on immunology and metabolism were analyzed using SPSS 
version 21.0. Significant differences between baseline and end 
of intervention were evaluated by paired t-test, while significant 
differences between treatments were evaluated by two-way 
analysis of variance (ANOVA) using the general linear model 
with Bonferroni correction. All data are shown as mean ±  SE. 
The statistical significance level was defined as p <  0.05 with 
p values represented in the figures as ***p < 0.001, **p < 0.01, 
and *p < 0.05. Effect of the different treatments on genus-level 
microbiota composition was assessed using ANOVA. The change 
in the relative abundance of each genus during each of the 
synbiotic and SCF treatments was compared to changes during 
the placebo treatment, keeping baseline abundance of the focal 
genus as a covariate in the model. p values were corrected for 
multiple testing using the false discovery rate method (21). The 
effect of treatments on overall microbiota was assessed using per-
mutational multivariate ANOVA (function adonis in R-package 
vegan) and principal coordinates analysis, using the Bray–Curtis 
dissimilarities (function capscale in R-package vegan).
rESUlTS
Blood lipids, Glucose, Cytokines, nK Cell 
activity, Phenotype, and intestinal 
Microbiota Composition
A total of 37 volunteers completed the study. Intestinal symp-
toms, anthropometric values and blood pressure of the volunteers 
are shown in Tables  1–3, respectively. Overall, no statistically 
significant differences were found. There were no significant 
differences between treatments for serum TC, HDL-cholesterol, 
LDL-cholesterol, triacylglycerol, NEFA, or glucose (Table  4). 
However, after analyzing blood lipid results from volunteers with 
raised cholesterol (TC > 5 mmol/L) at baseline (n = 26), a statisti-
cally significant decrease in TC and LDL-c was observed after 
synbiotic intervention with L. rhamnosus GG combined with 
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SCF, but not with the other treatments (Figure 3). Concentrations 
of IL-1β, IL-6, IL-8, IL-10, IL-12p70, TNF, and CRP were 
measured in serum. The cytokines IL-1β, IL-10, IL-12p70, and 
TNF were undetectable or only very low levels were found in 
the samples from elderly people (data not shown). Therefore, 
only IL-6, IL-8, and CRP results were analyzed (Table 5). Even 
though CRP serum concentrations of the subjects treated with 
L. rhamnosus GG-PB12 combined with SCF and SCF alone were 
higher than that with L. rhamnosus GG combined with SCF 
and placebo treatments, there were no significant differences 
between these. The use of SCF alone led to a decrease in the pro-
inflammatory cytokine IL-6, which was not observed with the 
synbiotics. Although highest numbers for NK cell activity were 
obtained after synbiotic treatments for all ratios, no significant 
differences were found (Figure 4A). Therefore, there was no effect 
of synbiotic on NK cell activities compared to other treatments. 
When NK cell activity was expressed on a per cell basis (divided 
by NK  cell percentage in lymphocytes), similar results were 
found (data not shown). When gender was considered, NK cell 
activity after L. rhamnosus GG combined with SCF interven-
tion almost reached significance for the E/T of 100 (p = 0.064) 
compared to baseline in females but not in males (Figure 4B). 
Furthermore, NK  cell activity at the beginning of the study 
was significantly higher in males than in females (Figure  4C). 
Interestingly, when dividing volunteers by age, i.e., 60–69 and 
70–80 years old, NK cell activity after L. rhamnosus GG combined 
with SCF intervention almost reached significance in the latter 
group (Figure  4D). Finally, L. rhamnosus GG-PB12 combined 
with SCF increased NK cell activity compared to SCF alone in 
older volunteers, showing tendency in E/T =  100 (p =  0.079) 
and significance when expressed as log E/T = 100 (p = 0.042). 
There were no significant effects of synbiotics on lymphocyte and 
NK cell phenotypes (data not shown). Quantities of the L. rham­
nosus GG strains and total bacteria, in feces, were measured using 
quantitative PCR (Table 6). Not surprisingly, increased numbers 
of L. rhamnosus GG or L. rhamnosus GG-PB12 were detected 
during intervention with the synbiotic in question, but not during 
placebo or SCF intervention. Impact of the interventions on total 
microbial communities was addressed by phylogenetic analysis 
of the fecal microbiota (Figure 5). L. rhamnosus GG combined 
with SCF, L. rhamnosus GG-PB12 combined with SCF, and SCF 
treatments had significant effects on overall microbiota composi-
tion when compared to baseline, each treatment explaining 2% 
of the variation in microbiota compositions (p  =  0.001). All 
active treatments caused a similar microbiota shift along prin-
cipal components 4 and 5, toward higher Parabacteroides and 
Ruminococcaceae abundance; the strongest shift was seen in L. 
rhamnosus GG combined with SCF and L. rhamnosus GG-PB12 
combined with SCF treatments. The placebo treatment did not 
have a significant impact compared to baseline levels on overall 
microbiota composition (R2 = 0.03, p = 0.95) compared to the 
baseline. Significant changes were detected in four bacterial gen-
era in the different treatments. Parabacteroides was significantly 
increased during both synbiotic treatments (L. rhamnosus GG: 
4.3% increase compared to placebo, p =  0.0004; L. rhamnosus 
GG-PB12: 3.4% increase, p = 0.0075). Ruminococcaceae Incertae 
sedis was increased significantly L. rhamnosus GG synbiotic 
TaBlE 5 | Cytokine production and C-reactive protein (CRP) concentrations expressed in millimolar as change from baseline and 3 weeks intervention study in the 
active [Lactobacillus rhamnosus GG + SCF, L. rhamnosus GG-PB12 + Soluble Corn Fiber (SCF), and only SCF] and placebo treatment groups (n = 37).
il-6 (pg/ml) Change from baseline il-8 (pg/ml) Change from baseline CrP (mg/l) Change from baseline
Placebo 0.710 ± 0.242 −0.126 ± 0.236 3.551 ± 0.380 0.063 ± 0.329 1.200 ± 0.180 0.436 ± 0.176
L. rhamnosus GG + SCF 0.988 ± 0.245 0.309 ± 0.242 3.650 ± 0.383 0.359 ± 0.337 1.209 ± 0.182 −0.091 ± 0.177
L. rhamnosus GG-PB12 + SCF 0.878 ± 0.245 0.197 ± 0.241 3.528 ± 0.382 −0.167 ± 0.336 1.244 ± 0.189 −0.342 ± 0.179*
SCF 0.658 ± 0.258 −0.072 ± 0.257* 3.447 ± 0.394 0.450 ± 0.365 1.375 ± 0.188 0.024 ± 0.180
Data shown as means ± SE.
*Significantly different from placebo (p < 0.05). Paired t-test.
FiGUrE 3 | Total cholesterol (a) and LDL-cholesterol concentrations (B) in each group after the treatment, in volunteers with raised cholesterol (total cholesterol 
>5 mmol/L) at baseline (n = 26) (*p < 0.05, **p < 0.01, and ***p < 0.001).
FiGUrE 4 | Natural killer cell activity in each group after the treatment. Data are mean ± SE. (a) Specific lysis after all treatments. (B) Specific lysis after 
LGG + Soluble Corn Fiber (SCF) intervention in females. E/T = 100/1. (C) Specific lysis at the beginning of the study in females and males. (D) Specific lysis after all 
treatments in the older group (70–80 years old) (n = 37).
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TaBlE 6 | Median quantities of total bacteria, Lactobacillus rhamnosus GG, and 
L. rhamnosus GG-PB12 in 23 fecal samples.
Treatment Totala lGGb PB12b Samples
LGG + SCF 5.881 × 1012 3.898 × 1010 N.D. 37
WO 4.653 × 1012 0.000 0.000 30
Placebo 4.757 × 1012 0.000 0.000 37
WO 4.887 × 1012 0.000 0.000 28
PB12 + SCF 5.429 × 1012 0.000 2.166 × 1010 37
WO 7.639 × 1012 0.000 0.000 26
SCF 5.919 × 1012 0.000 0.000 37
WO 6.100 × 1012 0.000 0.000 27
aQuantities as 16S rRNA gene copies/g feces.
bQuantities as CFU/g feces.
Samples: quantity of samples in the treatment in question.
WO, washout; N.D. indicates not detected; SCF, Soluble Corn Fiber.
FiGUrE 5 | Principal coordinate analysis (PCoA) of the fecal microbiota composition in each group after the treatments. (a) Score on components 4 and 5 in the 
PCoA plots shown as a box plot; (B) PCoA plots indicating the shift between baseline samples (gray) and treatment samples (red) of each participant arm: 
LGG + Soluble Corn Fiber (SCF)**, PB12 + SCF**, SCF** (**p = 0.001), and placebo (p = 0.95).
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treatment and treatment with SCF only (L. rhamnosus GG: 2.4% 
increase, p = 0.014; SCF: 2.4% increase, p = 0.015). A subtle, but 
significant, decrease in Oscillospira was detected following L. 
rhamnosus GG combined with SCF treatment (0.04%, p = 0.012), 
while a significant decrease in Desulfovibrio was detected during 
both synbiotic treatments (L. rhamnosus GG: 0.09% p =  0.011; 
L. rhamnosus GG-PB12: 0.1%, p = 0.0075).
DiSCUSSiOn
The health-promoting properties of probiotics are suggested to 
be strain dependent; therefore, strain identification and charac-
terization are essential (22). Probiotics elicit their functions in 
different ways, among which immunomodulation is suggested 
to be one mechanism (23). Current US national guidelines for 
CVD risk reduction are primarily focused on strategies to reduce 
concentrations of LDL-c, with the most recent focus being 
“lower is better” (23). Some components of the immune 
response, including phagocytosis, NK cell activity, and mucosal 
immunoglobulin A production, have been shown to be improved 
by certain probiotic bacterial strains, while other components, 
including lymphocyte proliferation, production of cytokines, 
and elevation of antibodies other than immunoglobulin A, 
appear to be less sensitive to probiotic modulation (24). NK cells 
are critical for the removal of intracellular pathogens and also 
possess vital tumoricidal activities, but their activity declines 
with aging (25), even though numbers of NK cells in the circula-
tion increase with age (26). NK cell activity has been demon-
strated to be enhanced by different probiotic strains studied in 
healthy adults (8, 9, 27) and in healthy older subjects (28, 29), 
Dong et  al. (30) showed that six different probiotic strains 
enhanced activation of all NK cell subsets and elicited similar 
capacity to stimulate NK  cell activities, without showing any 
strain-specific properties. This property of probiotic strains has 
been confirmed by human studies, in which oral consumption 
of Lactobacillus casei Shirota (LcS) (31), Lactobacillus fermen­
tum CECT5716 (32), Lactobacillus paracasei NCC 2461 (33), 
Bifidobacterium lactis HN019 (34, 35), or L. rhamnosus HN001 
(36, 37), enhanced NK cell activity in healthy adult or elderly 
populations. However, some human studies did not show any 
effect of probiotic strains (L. rhamnosus, B. lactis, LcS, 
Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/9, 
Bifidobacterium bifidum MF 20/5) on NK cell activity (38, 39), 
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perhaps due to differences in sample size, probiotic dose, con-
sumption period, study design, and volunteers. In our study, the 
L. rhamnosus GG combined with SCF intervention showed a 
tendency to increase NK cell activity compared to baseline in 
women. We found higher baseline NK activity values in males 
compared to females, which has been reported by other authors 
(7, 40), who also demonstrated that LcS consumption had a 
greater effect on female compared to male volunteers, and this 
effect might relate to an initially lower NK cell activity in females. 
Nagao et al. (41) have shown that daily intake of fermented milk 
containing LcS-enhanced NK  cell activity in healthy young 
subjects with relatively lower NK  cell activity. In the current 
study, after randomizing the volunteers by age, the L. rhamnosus 
GG combined with SCF intervention also showed a tendency to 
increase NK cell activity compared to baseline in elderly whose 
average age was 70–80 years. A possible lower baseline NK cell 
activity in this population could be related to the increase. It may 
then be suggested that the synbiotic does not necessarily enhance 
immune function above “normal” levels in healthy individuals, 
but rather modulates it back to normal levels in situations where 
immunity is impaired and thus plays a role in homeostasis, as 
previously reported for LcS (7). Flow cytometry analysis showed 
no difference in the relative proportion of NK cells and subsets 
in groups consuming the different treatments, suggesting that 
these synbiotics demonstrated a tendency to enhance NK cell 
activity but did not induce the expansion of NK cells. Overall, 
we have shown that synbiotic supplementation could slow down 
the reduction of NK  cell activity without changing the relative 
proportion of NK cells, as previously found by Morimoto et al. 
(42) for LcS. In fact, these authors reported that NK cells increas-
ing after supplementation of probiotics may be dependent on 
the species of lactic acid bacteria and/or the condition of the 
host (such as healthy subjects versus either cancer patients, or 
younger versus aged subjects, etc.). NK cell activity is important 
for immune surveillance against cancer and pathogenic infec-
tions (43, 44). On the other hand, environmental and psycho-
logical condition and NK cell activity are closely related (42). 
The reported effects of probiotics on cytokine production are 
complex and suggest strain-specific differences (31, 33). A range 
of cytokines was examined in the current study, but there were 
no significant changes in cytokine production by the synbiotics. 
Other human studies with probiotic interventions showed no 
changes in stimulated cytokine production (7, 45). In the present 
study, a significant decrease of pro-inflammatory IL-6 was only 
observed during the intervention with SCF and not in synbiotic 
combination. It is well known that appropriate dietary interven-
tion is an important way to impact on gut bacteria and subse-
quent functioning of the immune system (6), and prebiotics 
have demonstrable benefits. Shukla et  al. (46) reported that 
prebiotic supplementation modulated gut morphology and 
improved immune status in infected mice, while Marciano et al. 
(47) found that oligofructose decreased the concentration of 
IL-6 in rats. In the same way, Aliasgharzadeh et al. (48) observed 
that patients supplemented with resistant dextrin exhibited a 
significant decrease in IL-6 concentrations than those supple-
mented with maltodextrin. Childs et al. (49) demonstrated that 
XOS induced bifidogenesis, improved aspects of the plasma lipid 
profile, and modulated markers of immune function in healthy 
adults. A possible limitation associated with the study was that 
we did not specifically select subjects who were immunocom-
promised. The hypothesis of this study was that synbiotic 
intervention would at least partially reverse some of the decline 
in immune parameters caused by aging, although it cannot be 
ascertained whether the subjects in the current study were 
immunocompromised. Immune senescence is observed in 
healthy aging, and the purpose of this study was to investigate 
an older group, which was expected to have some degree of 
immune-senescence. It could be argued that the results from 
this study could also be applied to younger subjects and to those 
who are not necessarily immunocompromised. Finally, a limita-
tion of all studies employing immune biomarkers in the absence 
of clinical outcomes is that it is difficult to interpret the biologi-
cal significance of minor immunomodulatory effects. It is of 
specific interest to note that the reduction of these risk factors 
was only obtained with the synbiotic intervention L. rhamnosus 
GG combined with SCF but not the isogenic L. rhamnosus 
GG-PB12 that only differ in the production of mucus-binding 
pili (19). Furthermore, in regard to the fecal microbiota changes, 
an increased amount in the quantities of L. rhamnosus GG 
strains and L. rhamnosus GG-PB12 were detected during the 
intervention with the synbiotic in question, but not during pla-
cebo or SCF intervention. There are indications that L. rhamno­
sus GG persists longer in the intestinal tract of healthy adult 
volunteers than L. rhamnosus GG-PB12 (in preparation, 
Rasinkangas et  al.). We could not address this in the present 
study as assessment of persistence requires several samplings 
during the washout period. The 2-week washout was sufficient 
to eliminate effectively either of the L. rhamnosus strains. Both 
isogenic strains showed differential effects on the intestinal 
microbiota analysis and significant changes were detected in 
four bacterial genera. Parabacteroides was significantly increased 
during both synbiotic treatments, whereas a significant decrease 
in Oscillospira was observed. We also observed a significant 
decrease in numbers of Desulfovibrio spp. for both symbiotic 
treatments. This group of sulfate-reducing bacteria has been 
implied in as potential players in the etiology of various intesti-
nal disorders, including inflammatory bowel disease and colon 
cancer (50). Hence, their reduction by the synbiotic treatment 
with either of the L. rhamnosus GG strains may be a relevant 
example of their probiotic activity. As reported by Nakamura 
et  al. (51), the acetogens, methanogenic archaea, and sulfate-
reducing bacteria, which dispose the colonic hydrogen gas 
generated during fermentation, are low in abundance, but critical 
for functioning of the gut ecosystem. It is very likely that the 
organisms we found may be indicator species, particularly sensi-
tive to the environment and therefore informative of important 
structural or functional differences between ecosystems, which 
lead to the differential responses. Not surprisingly, Rumino­
coccaceae Incertae sedis was increased significantly during 
L. rhamnosus GG combined with SCF treatment and SCF treat-
ment alone, but the increase in SCF was more pronounced, 
indicating a possible role for this group as active plant degraders. 
The Ruminococcaceae are one of the most abundant families 
from the order Clostridiales found in the mammalian gut 
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environment, and have been associated with maintenance of gut 
health. Abundance estimates, based on 16S rRNA surveys, sug-
gest that Ruminococcaceae are the most abundant Firmicute 
families in gut environments, accounting for roughly 50 and 
30% of phylotypes, respectively (52, 53). One key point is that in 
gut environments the ability to degrade cellulose and hemicel-
lulose components of plant material enables members of the 
Ruminococcaceae to decompose substrates that are indigestible 
by the host. Declines in Ruminococcaceae and Parabacteroides 
have been identified as main microbial shifts associated with 
aging in mice (54, 55). The fact that the L. rhamnosus GG com-
bined with SCF treatment caused an increase specifically in 
these groups suggests that the treatment may have positive 
effects on the microbiota of elderly people. Elevated serum TC, 
LDL-c, and TAG concentrations and low HDL-c concentrations 
are well-established risk factors for CVD (56–58). Current US 
national guidelines for CVD risk reduction are primarily focused 
on strategies to reduce concentrations of LDL-c, with the most 
recent focus being “lower is better” (57). Based on meta-
regression analysis of randomized trials of statins, Delahoy et al. 
(59) concluded that there was a significant positive relationship 
between reductions in LDL-c and reductions in the risk for 
major cardiovascular events. To date, experimental and clinical 
studies have suggested that probiotic supplementation may have 
beneficial effects on serum lipid profiles. However, there are 
conflicting results on the efficacy of probiotic preparations in 
reducing serum cholesterol. Recently, Shimizu et  al. (60) 
evaluated the effects of probiotics on human serum lipid 
concentrations in a meta-analysis of interventional studies. 
Sadrzadeh-Yeganeh et  al. (61) have reported that probiotic 
interventions (including fermented milk products and probiot-
ics) produced changes in TC and LDL-c, while HDL-c and TAG 
concentrations did not differ significantly between probiotic and 
control groups. Moreover, they concluded that long-term (>4-
week) probiotic intervention was statistically more effective in 
decreasing TC and LDL-c than short-term (<4-week) interven-
tion. Interestingly, Shimizu et al. (60) found that decreases in TC 
and LDL-c concentrations during probiotic intervention were 
greater in mildly hypercholesterolemic than in normocholester-
olemic individuals. These results have been confirmed in our 
findings, since L. rhamnosus GG combined with SCF decreased 
TC and LDL-c compared to the other treatments in volunteers 
with raised cholesterol at baseline. Therefore, synbiotic inter-
vention will have more benefit in patients with hypercholester-
olemia than in individuals with normal lipid concentrations. In 
addition, reductions in TC and LDL-c in the elderly have been 
reported to be greater than those in younger individuals. This 
could be considered to be due to differences in baseline values, 
as in the elderly they were higher (2,010). Delahoy et  al. (62) 
suggested that a reduction of 1 mmol/L in LDL-c was associated 
with a 21% proportional reduction in the incidence of vascular 
events. Therefore, based on our present results, it is expected 
that synbiotic intervention in hypercholesterolemic patients 
would lead to an approximately 18% reduction in major cardio-
vascular events if a linear relationship between reduced LDL-c 
concentrations and reduced incidence of vascular events is 
assumed.
COnClUSiOn
We could conclude that L. rhamnosus GG combined with SCF 
intervention could be useful in the primary intervention of 
hypercholesterolemia and may lead to reductions in risk factors 
for CVD. The observed reduction of TC and LDL-c by L. rham­
nosus GG combined with SCF and not L. rhamnosus GG-PB12 
is of interest and may have various mechanistic explanations. 
First, L. rhamnosus GG showed a much higher mucus-binding 
capacity than L. rhamnosus GG-PB12 (19). Hence, L. rhamnosus 
GG is expected to reside in close proximity to intestinal cells, 
allowing for increased interactions. Second, the increased per-
sistence of L. rhamnosus GG may also impact the extent of host 
interactions. Both of these explanations imply that L. rhamnosus 
GG has beneficial host signaling capacity that affects TC and 
LDL-c concentrations. Third, L. rhamnosus GG has a differential 
effect on the total intestinal community and hence it cannot be 
excluded that the affected microbial community is involved in 
reduction of hypercholesteremia. Whatever the exact mechanism 
would be, the observation that TC and LDL-c concentrations 
were only reduced by an intervention with L. rhamnosus GG 
and not L. rhamnosus GG-PB12, provided evidence that the 
mucus-binding pili may confer a health influence. In conclusion, 
the synbiotic containing L. rhamnosus GG combined with SCF 
showed a tendency to promote innate immunity by increasing 
NK  cell activity in elderly women and in 70- to 80-year-old 
volunteers and decreased TC and LDL-c in hypercholesterolemic 
patients. In addition, L. rhamnosus LGG-PB12 combined with 
SCF demonstrated an increase in NK cell activity compared to 
SCF alone in older volunteers. We also found significant positive 
effects on the immune response, evidenced by a decrease of the 
pro-inflammatory cytokine IL-6. Therefore, dietary intervention 
with L. rhamnosus GG combined with SCF could be of impor-
tance in elderly as an attractive option for enhancement of both 
the microbial and immune systems.
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